Hepatitis C: all 2,356 studies
Page 15 of 24. Open to participants first (101), then studies with results posted, then the rest; newest registration first within each.
- SOF Plus DCV in Treating Chinese Treatment-experienced HCV PatientsCompletedNCT02473211Phase 2/3
- Way to Cure HCV AdherenceCompletedNCT02472925Not applicable
- Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b SubjectsCompletedNCT02470858Phase 2
- Neurocognitive Performance and Emotional State in HCV Patients With IFN-free Antiviral TherapyStatus unknownNCT02469012Not applicable
- Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV TreatmentActive, not recruitingNCT02460133Phase 4
- Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 InfectionCompletedNCT02452814
- Epidemic History and Iatrogenic Transmission of Blood-borne Viruses in Mid-20th Century KinshasaCompletedNCT02439918
- Transient Elastography to Assess Liver Fibrosis and Portal Hypertension in HCV Cirrhotic Patients Treated With New Antiviral Drugs (SPLEEN-C)CompletedNCT02439567Not applicable
- Biomarkers of Liver FibrosisTerminatedNCT02438917
- Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related QualityCompletedNCT02427204
- Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central AfricaCompletedNCT02405013Phase 2
- Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in TaiwanCompletedNCT02402699
- An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.WithdrawnNCT02397395Phase 2
- Epidemiology of Hepatitis C Virus Infection Among Opioid Substituted PatientsStatus unknownNCT02395198
- Prevalence and Screening of Hepatitis C in Belgium in 2015CompletedNCT02393365Not applicable
- A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4Status unknownNCT02371408Phase 2/3
- Comparative Assessment of Utilization of Antiviral Therapies in Hepatitis C and Effectiveness of Daclatasvir-containing Regimens in Real-life Clinical Care in Europe (CMPASS-EU)CompletedNCT02368522
- Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in African and Asian ImmigrantsCompletedNCT02366286
- The TAP Study: Treating People Who Inject Drugs in Community-Based Settings Using a Social Network ApproachStatus unknownNCT02363517Phase 3
- A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in CombinationCompletedNCT02362217Phase 1
- Determination of HCV Prevalence in a HIV Patient Cohort in Phnom Penh, CambodiaCompletedNCT02361541
- First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1CompletedNCT02339207Phase 1
- A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug UseCompletedNCT02336139Phase 2
- Qualification of Point-of-Care Assays for Management of HCV PatientsStatus unknownNCT02335320
- Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life ConditionsCompletedNCT02333292
- A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and AsunaprevirCompletedNCT02323594Phase 1
- Primary Prevention Hepatocellular Carcinoma by MetforminTerminatedNCT02319200Phase 3
- Comparing Brief Alcohol Interventions For HIV-HCV Co-infected PersonsCompletedNCT02316184Not applicable
- Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034.TerminatedNCT02315638
- HepNet Acute HCV IV - LDV/SOF FDC in Acute Genotype 1 Hepatitis C Virus InfectionCompletedNCT02309918Phase 2
- Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin RegimenWithdrawnNCT02309450Phase 2
- Phase I-II Vaccination of Autologous Dendritic Cells Transduced With Adenoviral Vector Encoding NS3 in Hepatitis C Encoding NS3 in Hepatitis CTerminatedNCT02309086Phase 1/2
- Improving Fibrosis Outcomes With MetforminWithdrawnNCT02306070Phase 2
- Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV CoinfectionCompletedNCT02294136Not applicable
- Liver Test Study of Using JKB-122 in Hepatitis C Virus (HCV)-Positive Patients Nonresponsive to Prior Interferon Based TherapiesTerminatedNCT02293941Phase 2
- Impact of HCV Treatment on Neurocognitive Functions and Brain MetabolismWithdrawnNCT02292966Phase 4
- Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV PatientsCompletedNCT02282709Phase 3
- An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus InfectionCompletedNCT02278419Phase 2
- Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003)CompletedNCT02269059Phase 1
- Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV InfectionStatus unknownNCT02261662Not applicable
- Evaluation of the Antiviral Pharmacodynamic Effect, Safety, and Pharmacokinetics of Escalating Doses of BILB 1941 ZW to Patients With Chronic Hepatitis C Genotype 1 Virus InfectionCompletedNCT02254707Phase 1/2
- Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus InfectionCompletedNCT02253550Phase 2
- Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis CCompletedNCT02250001
- Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Chronic Hepatitis C Virus InfectionCompletedNCT02226952Phase 1/2
- Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis CCompletedNCT02226939Phase 2
- Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot StudyCompletedNCT02220868Phase 4
- Effect of Camel Milk on Chronic Hepatitis CCompletedNCT02216045Phase 2
- Safety Study of the Aethlon HemopurifierTerminatedNCT02215902Not applicable
- Treatment of Chronic HCV Infected Egyptian Patients With Electromagnetic Waves and Herbal TherapyStatus unknownNCT02215525Phase 3
- A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis CWithdrawnNCT02206932Phase 4
- Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)WithdrawnNCT02204475Phase 3
- Hepatic Safety of Eviplera® in HIV/Hepatitis C (HCV)-Coinfected Patients Without HCV Treatment in the "The HEPAVIR HEPATIC SAFETY Cohort."CompletedNCT02196064
- An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced CirrhosisCompletedNCT02195440Phase 1
- Rapid Diagnostics for HIV and HepatitisWithdrawnNCT02190305Not applicable
- Hepatitis C Alcohol Reduction TreatmentCompletedNCT02176980Not applicable
- Study of Drug Combination on Pharmacokinetics in Healthy VolunteersCompletedNCT02175602Phase 1
- Two-way Interaction Between Alisporivir and EDP239CompletedNCT02173574Phase 1
- An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver TransplantCompletedNCT02165189Phase 2
- Pirfenidone, an Antifibrotic and Antiinflammatory DrugCompletedNCT02161952Phase 2
- A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis CNo longer availableNCT02161939
- Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Participants With Hepatitis C (MK-2248-002)CompletedNCT02161510Phase 1
- DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral)CompletedNCT02156570Phase 4
- A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin.Status unknownNCT02150291Phase 4
- Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT02143401Phase 1
- Patient-Centered Care and Asian AmericansCompletedNCT02139722Not applicable
- Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) InfectionStatus unknownNCT02126137Phase 1
- Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infectionCompletedNCT02125500Phase 2
- UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis CCompletedNCT02123654Phase 3
- Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis CCompletedNCT02123212Not applicable
- Implementation of a Sexual Health Intervention for Young Men Who Have Sex With Men (MSM) in Two Vietnamese CitiesCompletedNCT02122094Not applicable
- Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis CTerminatedNCT02120274Phase 4
- TD-6450 MAD Study in HCV Infected SubjectsCompletedNCT02116543Phase 1
- DVD-based HIV/HCV Prevention Intervention for Drug-Involved Latino Criminal Justice ClientsCompletedNCT02116179Not applicable
- Comparative Effectiveness and Tolerability of Boceprevir vs TelaprevirCompletedNCT02113631Not applicable
- Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected SubjectsTerminatedNCT02112942Phase 1
- Boceprevir in End Stage Renal Disease (ESRD)WithdrawnNCT02112630Not applicable
- Absolute Bioavailability of BMS-791325CompletedNCT02112110Phase 1
- To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination TabletCompletedNCT02108639Phase 1
- Hepatitis C in Renal Transplant RecipientsStatus unknownNCT02108301Phase 4
- Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)CompletedNCT02107365Phase 2
- Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and RosuvastatinCompletedNCT02104843Phase 1
- A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With SimeprevirCompletedNCT02103699
- Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325CompletedNCT02103569Phase 1
- Control and Elimination Within Australia of Hepatitis C From People Living With HIVStatus unknownNCT02102451
- Evaluation of the National Treatment Program of Hepatitis C in EgyptWithdrawnNCT02101177
- Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis CWithdrawnNCT02099604Phase 3
- Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C VirusCompletedNCT02098616Not applicable
- EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis CNo longer availableNCT02097966
- Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325CompletedNCT02095860Phase 1
- Telaprevir in Genotype 3 HCVCompletedNCT02087111Phase 4
- Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy SubjectsCompletedNCT02084953Phase 1
- Comparison of OraQuick HCV Rapid Antibody Test and Standard Serologic Screening for Hepatitis C: Validity, Acceptability and Impact on Linkage to CareTerminatedNCT02084719Not applicable
- Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy OutcomeCompletedNCT02083367
- Technology-Based Application To Improve The Triple Therapy Adherence Rate In Subjects With Hepatitis C InfectionWithdrawnNCT02070107Not applicable
- Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for TestingCompletedNCT02068963
- Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C PatientsCompletedNCT02065999
- Surveillance and Treatment of Prisoners With Hepatitis CCompletedNCT02064049Phase 4
- The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C PatientsCompletedNCT02063607Phase 1
- "Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study"CompletedNCT02058173Phase 4
- Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A)Status unknownNCT02057887Phase 1/2